Remote Conditioned Donor Blood for Ischemia-Reperfusion Injury
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional blood transfusions often trigger massive systemic inflammatory responses and are limited by the need for time-consuming remote conditioning procedures, which may not be feasible in emergency situations or when access to suitable tissue beds is unavailable.
Innovation Solution
Subjecting donors to remote conditioning prior to blood collection to release biologically active substances, which are then collected and processed into blood-derived products that can be administered to treatment subjects to reduce inflammation and provide health benefits without the need for direct remote conditioning on the recipient.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional remote conditioning procedures are applied to treatment subjects, then protection against ischemia-reperfusion injury is achieved, but the procedure is time-consuming and not feasible in emergency situations
Solution Approach 1:
The invention applies remote conditioning to donors before blood collection, so that the protective effects are already present in the blood when transfused to the treatment subject. This eliminates the need to perform time-consuming remote conditioning procedures on the treatment subject in emergency situations, while still achieving protection against ischemia-reperfusion injury.
Solution Approach 2:
The invention uses donor blood as an intermediary to transfer the protective effects of remote conditioning from the donor to the treatment subject. The blood acts as a carrier that delivers bioactive substances and protective mechanisms without requiring direct application of the conditioning procedure to the treatment subject.
2Reliability
If traditional blood transfusions are administered to treatment subjects, then blood volume and organ perfusion are restored, but massive systemic inflammatory response is triggered
Solution Approach 1:
The invention applies remote conditioning to donors before blood collection to pre-activate protective mechanisms that counteract inflammation. This preliminary anti-action ensures that the transfused blood contains substances that will mitigate the inflammatory response when administered to the treatment subject, while still restoring blood volume and organ perfusion.
Solution Approach 2:
The invention changes the biochemical parameters of the blood by subjecting donors to remote conditioning, which alters the composition and properties of the blood. This results in blood with modified inflammatory profiles and enhanced protective capabilities, allowing restoration of blood volume without triggering massive systemic inflammation.
3Reliability
If remote conditioning is applied to treatment subjects, then health benefits are achieved, but access to suitable tissue beds may not be available in severe trauma situations
Solution Approach 1:
The invention uses donor blood as an intermediary to deliver the health benefits of remote conditioning without requiring direct access to the treatment subject's tissue beds. The blood carries protective bioactive substances from the donor (who received remote conditioning) to the treatment subject, making the therapy feasible even when tissue bed access is unavailable due to severe trauma.
Solution Approach 2:
The invention creates a form of 'copying' the remote conditioning effect by transferring it through donor blood. Instead of directly applying the conditioning procedure to the treatment subject (which requires tissue bed access), the protective effects are copied and delivered via the transfused blood, bypassing the need for direct tissue access.
Data Source
AI summary
Treatment methods are described using blood collected from a donor after subjecting thereof to remote conditioning such as remote ischemic conditioning via several episodes of short-term limb occlusion. Blood containing remote conditioning substances or a biologically active preparation containing such substances may be stored and used at a future time to afford a health benefit to the treatment subject. Extraction of remote conditioning substances may be done extracorporeally using dialysis or other blood processing methods following by returning of blood to the donor. Extraction of remote conditioning substances may be done during the time periods of their maximum presence in donor blood.